Compare $NNVC vs $QNCX | Chartloom

Compare

$NNVC vs $QNCX

NanoViricides, Inc · Quince Therapeutics Inc

NNVC

NanoViricides, Inc

QNCX

Quince Therapeutics Inc

Compare $NNVC vs $QNCX

Comparing NanoViricides, Inc and Quince Therapeutics Inc

NNVCNanoViricides, Inc

QNCXQuince Therapeutics Inc

NNVCNanoViricides, Inc

Market cap

$33M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

7.4%

52W performance

-9.1%

FCF yield

-23.6%

QNCXQuince Therapeutics Inc

Market cap

$31M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-94.7%

52W performance

-91.7%

FCF yield

-151.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NNVC

QNCX

Detailed metrics comparison

NNVC

NanoViricides, Inc

QNCX

Quince Therapeutics Inc

Market Cap

NNVC$33M

QNCX$31M

Enterprise Value

NNVC$30M

QNCX$-85M

Price

NNVC$1.30

QNCX$31.73

P/E Ratio

NNVCN/A

QNCXN/A

P/S Ratio

NNVC0.00x

QNCX0.00x

EV/Sales

NNVC0.00x

QNCX0.00x

EV/EBITDA

NNVC0.00x

QNCX0.00x

P/B Ratio

NNVC3.76x

QNCX0.27x

P/FCF Ratio

NNVCN/A

QNCXN/A

EV/FCF

NNVC-3.88x

QNCX1.81x

PEG Ratio

NNVCN/A

QNCXN/A

Forward P/E (NTM)

NNVCN/A

QNCXN/A

Forward P/S (NTM)

NNVCN/A

QNCXN/A

Revenue (TTM)

NNVC$0

QNCX$0

Revenue Growth (YoY)

NNVCN/A

QNCXN/A

Forward Rev Growth

NNVC0.0%

QNCX114.8%

Gross Margin (TTM)

NNVC0.0%

QNCX0.0%

Operating Margin (TTM)

NNVC0.0%

QNCX0.0%

EBITDA Margin (TTM)

NNVC0.0%

QNCX0.0%

Net Margin (TTM)

NNVC0.0%

QNCX0.0%

FCF Margin (TTM)

NNVCN/A

QNCXN/A

Net Income (TTM)

NNVC$-8M

QNCX$-92M

FCF (TTM)

NNVC$-8M

QNCX$-47M

EPS (TTM)

NNVC-$0.37

QNCX-$15.08

ROE (TTM)

NNVC-9111.0%

QNCX-12702.0%

ROA (TTM)

NNVC-8074.0%

QNCX-10448.0%

ROIC (TTM)

NNVC-9111.0%

QNCX-11143.0%

Cash

NNVC$3M

QNCX$116M

Debt

NNVC$0

QNCX$0

Net Cash/Debt

NNVC$3M

QNCX$116M

Current Ratio (TTM)

NNVC2.66x

QNCX14.52x

Quick Ratio (TTM)

NNVC2.35x

QNCX14.28x

Debt/Equity (TTM)

NNVC0.00x

QNCX0.48x

Debt/Assets (TTM)

NNVC0.0%

QNCX0.0%

Interest Coverage (TTM)

NNVCN/A

QNCXN/A

Net Debt/EBITDA (TTM)

NNVC0.00x

QNCX0.00x

Beta

NNVC1.91

QNCX1.80

52W Performance

NNVC-9.1%

QNCX-91.7%

YTD Performance

NNVC7.4%

QNCX-94.7%

% from 52W High

NNVC-41.7%

QNCX-96.5%

% from 52W Low

NNVC52.9%

QNCX110.1%

Asset Turnover (TTM)

NNVC0.00x

QNCX0.00x

FCF Yield (TTM)

NNVC-23.6%

QNCX-151.2%

Earnings Yield (TTM)

NNVC-24.9%

QNCX-297.4%

Dividend Yield (TTM)

NNVCN/A

QNCXN/A

Rule of 40

NNVC0.0

QNCX0.0

EV/GP/RG

NNVCN/A

QNCXN/A

Ticker research

View NNVC research View QNCX research

Metric	NNVC NanoViricides, Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$33M	$31M
Enterprise Value	$30M	$-85M
Price	$1.30	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.76x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.88x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-92M
FCF (TTM)	$-8M	$-47M
EPS (TTM)	-$0.37	-$15.08
ROE (TTM)	-9111.0%	-12702.0%
ROA (TTM)	-8074.0%	-10448.0%
ROIC (TTM)	-9111.0%	-11143.0%
Financial Health
Cash	$3M	$116M
Debt	$0	$0
Net Cash/Debt	$3M	$116M
Current Ratio (TTM)	2.66x	14.52x
Quick Ratio (TTM)	2.35x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.80
52W Performance	-9.1%	-91.7%
YTD Performance	7.4%	-94.7%
% from 52W High	-41.7%	-96.5%
% from 52W Low	52.9%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-23.6%	-151.2%
Earnings Yield (TTM)	-24.9%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NNVC research	View QNCX research

Valuation

P/S Ratio

NNVC

0.00x

QNCX

0.00x

EV/FCF

NNVC

-3.88x

QNCX

1.81x

Growth & revenue

Forward Revenue Growth

QNCX

114.8%

NNVC

0.0%

Profitability & performance

Gross Margin

NNVC

0.0%

QNCX

0.0%

ROE

NNVC

-9111.0%

QNCX

-12702.0%

FCF Yield %

NNVC

-23.6%

QNCX

-151.2%

52-Week Performance

NNVC

-9.1%

QNCX

-91.7%

Detailed metrics comparison

NNVC

NanoViricides, Inc

QNCX

Quince Therapeutics Inc

Market Cap

NNVC$33M

QNCX$31M

Enterprise Value

NNVC$30M

QNCX$-85M

Price

NNVC$1.30

QNCX$31.73

P/E Ratio

NNVCN/A

QNCXN/A

P/S Ratio

NNVC0.00x

QNCX0.00x

EV/Sales

NNVC0.00x

QNCX0.00x

EV/EBITDA

NNVC0.00x

QNCX0.00x

P/B Ratio

NNVC3.76x

QNCX0.27x

P/FCF Ratio

NNVCN/A

QNCXN/A

EV/FCF

NNVC-3.88x

QNCX1.81x

PEG Ratio

NNVCN/A

QNCXN/A

Forward P/E (NTM)

NNVCN/A

QNCXN/A

Forward P/S (NTM)

NNVCN/A

QNCXN/A

Revenue (TTM)

NNVC$0

QNCX$0

Revenue Growth (YoY)

NNVCN/A

QNCXN/A

Forward Rev Growth

NNVC0.0%

QNCX114.8%

Gross Margin (TTM)

NNVC0.0%

QNCX0.0%

Operating Margin (TTM)

NNVC0.0%

QNCX0.0%

EBITDA Margin (TTM)

NNVC0.0%

QNCX0.0%

Net Margin (TTM)

NNVC0.0%

QNCX0.0%

FCF Margin (TTM)

NNVCN/A

QNCXN/A

Net Income (TTM)

NNVC$-8M

QNCX$-92M

FCF (TTM)

NNVC$-8M

QNCX$-47M

EPS (TTM)

NNVC-$0.37

QNCX-$15.08

ROE (TTM)

NNVC-9111.0%

QNCX-12702.0%

ROA (TTM)

NNVC-8074.0%

QNCX-10448.0%

ROIC (TTM)

NNVC-9111.0%

QNCX-11143.0%

Cash

NNVC$3M

QNCX$116M

Debt

NNVC$0

QNCX$0

Net Cash/Debt

NNVC$3M

QNCX$116M

Current Ratio (TTM)

NNVC2.66x

QNCX14.52x

Quick Ratio (TTM)

NNVC2.35x

QNCX14.28x

Debt/Equity (TTM)

NNVC0.00x

QNCX0.48x

Debt/Assets (TTM)

NNVC0.0%

QNCX0.0%

Interest Coverage (TTM)

NNVCN/A

QNCXN/A

Net Debt/EBITDA (TTM)

NNVC0.00x

QNCX0.00x

Beta

NNVC1.91

QNCX1.80

52W Performance

NNVC-9.1%

QNCX-91.7%

YTD Performance

NNVC7.4%

QNCX-94.7%

% from 52W High

NNVC-41.7%

QNCX-96.5%

% from 52W Low

NNVC52.9%

QNCX110.1%

Asset Turnover (TTM)

NNVC0.00x

QNCX0.00x

FCF Yield (TTM)

NNVC-23.6%

QNCX-151.2%

Earnings Yield (TTM)

NNVC-24.9%

QNCX-297.4%

Dividend Yield (TTM)

NNVCN/A

QNCXN/A

Rule of 40

NNVC0.0

QNCX0.0

EV/GP/RG

NNVCN/A

QNCXN/A

Ticker research

View NNVC research View QNCX research

Metric	NNVC NanoViricides, Inc	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$33M	$31M
Enterprise Value	$30M	$-85M
Price	$1.30	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.76x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.88x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-8M	$-92M
FCF (TTM)	$-8M	$-47M
EPS (TTM)	-$0.37	-$15.08
ROE (TTM)	-9111.0%	-12702.0%
ROA (TTM)	-8074.0%	-10448.0%
ROIC (TTM)	-9111.0%	-11143.0%
Financial Health
Cash	$3M	$116M
Debt	$0	$0
Net Cash/Debt	$3M	$116M
Current Ratio (TTM)	2.66x	14.52x
Quick Ratio (TTM)	2.35x	14.28x
Debt/Equity (TTM)	0.00x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.80
52W Performance	-9.1%	-91.7%
YTD Performance	7.4%	-94.7%
% from 52W High	-41.7%	-96.5%
% from 52W Low	52.9%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-23.6%	-151.2%
Earnings Yield (TTM)	-24.9%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NNVC research	View QNCX research